Effect of irisin on hypoxic-ischemic brain damage in neonatal rats
XU Xuan-Pei1, HUANG Ling-Yi2, ZHAO Feng-Yan1, YING Jun-Jie1, LI Shi-Ping1, YUE Yan1, LI Wen-Xing1, QU Yi1, MU De-Zhi1
Department of Pediatrics, West China Second University Hospital/Key Laboratory of Birth Defects and Related Diseases of Women and Children(Sichuan University), Ministry of Education, Chengdu 610041, China
Abstract Objective To study the effect and mechanism of action of irisin on hypoxic-ischemic brain damage in neonatal rats. Methods A total of 248 7-day-old Sprague-Dawley rats were randomly divided into a sham-operation group, a model group, and low-and high-dose irisin intervention groups (n=62 each). The rats in the model and irisin intervention groups were given hypoxic treatment after right common carotid artery ligation to establish a model of hypoxic-ischemic brain damage. Those in the sham-operation group were given the separation of the right common carotid artery without ligation or hypoxic treatment. The rats in the high-and low-dose irisin intervention groups were given intracerebroventricular injection of recombinant irisin polypeptide at a dose of 0.30 μg and 0.15 μg respectively. Those in the model and sham-operation groups were given the injection of an equal volume of PBS. The water maze test was used to compare neurological behaviors between groups. TTC staining, hematoxylin-eosin staining and TUNEL staining were used to observe histopathological changes of the brain. Western blot was used to measure the expression of the apoptosis-related molecules cleaved-caspase-3 (CC3), BCL-2 and BAX. Results Compared with the sham-operation group, the model group had a significant increase in latency time and a significant reduction in the number of platform crossings (P P P P P Conclusions Irisin can alleviate hypoxic-ischemic brain damage in neonatal rats in a dose-dependent manner, possibly by reducing cell apoptosis in the cerebral cortex and the hippocampus.
Yıldız EP, Ekici B, Tatlı B. Neonatal hypoxic ischemic encephalopathy:an update on disease pathogenesis and treatment[J]. Expert Rev Neurother, 2017, 17(5):449-459.
[2]
Wassink G, Davidson JO, Dhillon SK, et al. Therapeutic hypothermia in neonatal hypoxic-ischemic encephalopathy[J]. Curr Neurol Neurosci Rep, 2019, 19(2):2.
[3]
Rao R, Trivedi S, Vesoulis Z, et al. Safety and short-term outcomes of therapeutic hypothermia in preterm neonates 34-35 weeks gestational age with hypoxic-ischemic encephalopathy[J]. J Pediatr, 2017, 183:37-42.
[4]
Boström P, Wu J, Jedrychowski MP, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis[J]. Nature, 2012, 481(7382):463-468.
[5]
Ruan Q, Zhang L, Ruan J, et al. Detection and quantitation of irisin in human cerebrospinal fluid by tandem mass spectrometry[J]. Peptides, 2018, 103:60-64.
[6]
Aydin S, Kuloglu T, Aydin S. Copeptin, adropin and irisin concentrations in breast milk and plasma of healthy women and those with gestational diabetes mellitus[J]. Peptides, 2013, 47:66-70.
[7]
Aydin S, Aydin S, Kuloglu T, et al. Alterations of irisin concentrations in saliva and serum of obese and normal-weight subjects, before and after 45 min of a Turkish bath or running[J]. Peptides, 2013, 50:13-18.
[8]
Yıldız EP, Ekici B, Tatlı B. Neonatal hypoxic ischemic encephalopathy:an update on disease pathogenesis and treatment[J]. Expert Rev Neurother, 2017, 17(5):449-459.
[9]
Chen K, Xu Z, Liu Y, et al. Irisin protects mitochondria function during pulmonary ischemia/reperfusion injury[J]. Sci Transl Med, 2017, 9(418). pii:eaao6298.
[10]
Siddiqui WA, Ahad A, Ahsan H. The mystery of BCL2 family:Bcl-2 proteins and apoptosis:an update[J]. Arch Toxicol, 2015, 89(3):289-317.
[11]
Charriaut-Marlangue C, Besson VC, Baud O. Sexually dimorphic outcomes after neonatal stroke and hypoxia-ischemia[J]. Int J Mol Sci, 2017, 19(1). pii:E61.
[12]
Zheng Z, Zhang L, Qu Y, et al. Mesenchymal stem cells protect against hypoxia-ischemia brain damage by enhancing autophagy through brain derived neurotrophic factor/mammalin target of rapamycin signaling pathway[J]. Stem Cells, 2018, 36(7):1109-1121.
[13]
Asadi Y, Gorjipour F, Behrouzifar S, et al. Irisin peptide protects brain against ischemic injury through reducing apoptosis and enhancing BDNF in a rodent model of stroke[J]. Neurochem Res, 2018, 43(8):1549-1560.
[14]
Gopagondanahalli KR, Li J, Fahey MC, et al. Preterm hypoxic-ischemic encephalopathy[J]. Front Pediatr, 2016, 4:114.
[15]
Bi J, Zhang J, Ren Y, et al. Irisin alleviates liver ischemia-reperfusion injury by inhibiting excessive mitochondrial fission, promoting mitochondrial biogenesis and decreasing oxidative stress[J]. Redox Biol, 2019, 20:296-306.
[16]
Liao Q, Qu S, Tang LX, et al. Irisin exerts a therapeutic effect against myocardial infarction via promoting angiogenesis[J]. Acta Pharmacol Sin, 2019, 40(10):1314-1321.
[17]
Thornton C, Leaw B, Mallard C, et al. Cell death in the developing brain after hypoxia-ischemia[J]. Front Cell Neurosci, 2017, 11:248.
[18]
Thornton C, Hagberg H. Role of mitochondria in apoptotic and necroptotic cell death in the developing brain[J]. Clin Chim Acta, 2015, 451(Pt A):35-38.
[19]
Walensky LD. Targeting BAX to drug death directly[J]. Nat Chem Biol, 2019, 15(7):657-665.
